Zipyran Plus 50 mg + 145 mg + 150 mg Tabletka

Authorised

- Praziquantel
- Pyrantel embonate
- Febantel

Product identification

Medicine name:
Zipyran Plus 50 mg + 145 mg + 150 mg Tabletka

Active substance:
Praziquantel

Pyrantel embonate

Febantel

Target species:
Dog

Route of administration:
Oral use

Product details

Active substance and strength:
Praziquantel
50.00 milligram(s) / 1.00 Tablet

Pyrantel embonate

145.00 milligram(s) / 1.00 Tablet

Febantel
150.00 milligram(s) / 1.00 Tablet

Pharmaceutical form:
Tablet

Withdrawal period by route of administration:
Oral use:

- **Dog**

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QP52AC05

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

Authorisation status:
Valid

Authorised in:
Poland

Package description:
Available only in Polish
Available only in Polish
Available only in Polish

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Full application (Article 12(3) of Directive No 2001/82/EC)

Marketing authorisation holder:

Laboratorios Calier S.A.

Marketing authorisation date:
30/06/2003

Manufacturing sites for batch release:
Laboratorios Calier S.A.

Responsible authority:
Office For Registration Of Medicinal Products Medical Devices And Biocidal Products

Authorisation number:
1363

Date of authorisation status change:
30/06/2003

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.

Labelling

This document does not exist in this language (English). You can find it in another language below.

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.

Source URL: *https://medicines.health.europa.eu/veterinary/600000059981*